Silver Spring, MD—At the board meeting on March 8, 2022, the American Herbal Products Association (AHPA) Board of Trustees chartered the AHPA Psychedelic Plants and Fungi Committee, according to a press release.

The purpose of the committee will be to address issues related to the safe use and responsible commerce of lawfully marketed products derived from psychedelic plants and fungi. Elan Sudberg, CEO of Alkemist Labs, was appointed as the committee’s first chair.

Those interested in joining the committee are asked to contact Michael McGuffin, who will serve as staff liaison, atmmcguffin@ahpa.org.

Related: 2022 AHPA Awards Recognize Those Making a Difference Dr. Bronner’s Takes Steps to Offer Employees Psychedelic Assisted Therapy Naturally Informed Education: Psychedelic Therapy

“With the emergence of legal psychedelics being professionally used to address major mental health issues, and research finding significant benefits in that context, it’s crucial that the category be developed with experience and deliberation,” said Sudberg. “Given that AHPA's mission is to promote the responsible and sustainable commerce of herbal products to ensure that consumers have informed access to a wide variety of safe herbal goods, it’s entirely appropriate that AHPA’s expertise be utilized to help that sector grow responsibly.”